News
IMUX
1.180
-7.09%
-0.090
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)
TipRanks · 3d ago
Weekly Report: what happened at IMUX last week (0408-0412)?
Weekly Report · 4d ago
Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
Piper Sandler published the top 10 stocks with upwards and downwards daily percentage change as of Thursday. The S&P 500 (SP500) is vulnerable to a possible 5-10% pullback in upcoming weeks or months, analysts say. High-interest rates, inflation, and mediocre breadth are making the market vulnerable to pullback, Piper Sandler says.
Seeking Alpha · 04/12 15:34
Immunic, Inc. (NASDAQ:IMUX): When Will It Breakeven?
Immunicic, Inc. Develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. The biotechnology company posted a loss of US$94m in its most recent financial year. The company is projected to become profitable around 2 years from now. An average annual growth rate of 58% is expected for Immunic to reach breakeven.
Simply Wall St · 04/11 11:10
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)
TipRanks · 04/10 11:20
Weekly Report: what happened at IMUX last week (0401-0405)?
Weekly Report · 04/08 09:19
Brookline Capital starts Immunic at buy, cites MS drug candidate
Healthcare Brookline Capital starts Immunic at buy, cites MS drug candidate IMU-838. Investment firm cites potential of the company’s multiple sclerosis drug candidate. The firm set its price target for the stock at $10, citing the potential of Immunic.
Seeking Alpha · 04/05 17:00
Immunic Initiated at Buy by Brookline Capital
Dow Jones · 04/05 09:09
Immunic Price Target Announced at $10.00/Share by Brookline Capital
Dow Jones · 04/05 09:09
Brookline Capital Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $10
Benzinga · 04/05 08:59
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Shockwave Medical (SWAV)
TipRanks · 04/05 08:50
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
Immunic, Inc. Is developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company will host a Multiple Sclerosis (MS) Research and Development Day in April. The company also will participate in the following investor conferences.
Barchart · 04/04 05:30
Weekly Report: what happened at IMUX last week (0325-0329)?
Weekly Report · 04/01 09:19
Weekly Report: what happened at IMUX last week (0318-0322)?
Weekly Report · 03/25 09:19
Catalyst Watch: Walgreens earnings, UPS analyst day and Xiaomi's luxury EV debut
Seeking Alpha's Catalyst Watch looks at next week's key events. Options trading volume is elevated on Digital World Acquisition (DWAC) ahead of the potential listing of Trump Media & Technology. The Nevada Gaming Control Board report for February will be released. United Parcel Service (UPS) will hold its Analyst Day.
Seeking Alpha · 03/22 19:00
Immunic Gets Allowance for Vidofludimus Calcium Patent Application
Biotechnology company Immunic has received a Notice of Allowance from the U.S. Patent and Trademark Office. The claims are expected to provide protection into 2039. The patent application covers calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative.
Dow Jones · 03/20 10:51
Weekly Report: what happened at IMUX last week (0311-0315)?
Weekly Report · 03/18 09:19
Weekly Report: what happened at IMUX last week (0304-0308)?
Weekly Report · 03/11 09:19
Immunic Inc: Statement of changes in beneficial ownership of securities
Press release · 03/07 08:12
Weekly Report: what happened at IMUX last week (0226-0301)?
Weekly Report · 03/04 09:19
More
Webull provides a variety of real-time IMUX stock news. You can receive the latest news about Immunic Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMUX
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.